Novartis’s Cosentyx May Emerge as a Leading Psoriasis Drug
Novartis: What Are the Major Growth Drivers for 2018? On January 16, 2018, Novartis (NVS) released data from its Phase 3b trial, CLARITY. This release highlighted the superiority of Cosentyx compared to Johnson & Johnson’s (JNJ) Stelara in clearing skin in patients with moderate to severe psoriasis at the end of 12 weeks and 16 weeks of therapy.